The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Trimel Pharmaceuticals Corp

TSX: TRL
Delayed quote

$0.79

Today's change+0.01 +1.28%
Updated March 27 3:59 PM EDT. Delayed by at least 15 minutes.
 

Trimel Pharmaceuticals Corp

TSX: TRL
Delayed quote

$0.79

Today's change+0.01 +1.28%
Updated March 27 3:59 PM EDT. Delayed by at least 15 minutes.

Trimel Pharmaceuticals Corp crosses above 20-day moving average

Trimel Pharmaceuticals Corp closed up Friday by $0.01 or 1.28% to $0.79 and crossing above its 20-day moving average. Shares have lost 3.66% over the last five days, but have gained 12.86% over the last year to date. This security has outperformed the S&P TSX by 8.39% during the last year.

Key company metrics

  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield--
  • Trailing EPS-$0.15
Updated March 27 3:59 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-525.13%

Trimel Pharmaceuticals Corp has a net profit margin of -525.13%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.39%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2014Q3/2014Q2/2014Q1/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014
Revenue3200
Total other revenue--------
Total revenue3200
Gross profit-50----
Total cost of revenue72----
Total operating expense9764
Selling / general / administrative1111
Research & development1142
Depreciation / amortization0011
Interest expense (income), net operating--------
Unusual expense (income)020--
Other operating expenses, total--------
Operating income-7-5-6-4
Interest income (expense), net non-operating-1-100
Gain (loss) on sale of assets--------
Other--------
Income before tax-8-5-7-3
Income after tax-8-5-7-3
Income tax, total0000
Net income-8-5-7-3
Total adjustments to net income0------
Net income before extra. items-8-5-7-3
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-8-5-7-3
Inc. avail. to common incl. extra. items-8-5-7-3
Diluted net income-8-5-7-3
Dilution adjustment0----0
Diluted weighted average shares201186163155
Diluted EPS excluding extraordinary itemsvalue per share-0.04-0.02-0.05-0.02
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-0.04-0.01-0.05-0.02